Along with our interdisciplinary team of scientists, health policy experts, and regulatory experts, Janine Pillitteri works with pharmaceutical and consumer health care clients in the areas of Rx-to-OTC switch, risk management, and tobacco control and harm minimization. Janine is involved in the development and oversight of pharmaceutical studies supporting Rx-to-OTC switch projects including post-marketing surveillance and consumer behavioral research such as label comprehension studies, self-selection studies, actual use trials, and human factors studies.
To help clients prepare for regulatory submissions, FDA interactions, and advisory committee meetings, her work in this area includes qualitative and quantitative research design, protocol development, the design and testing of questionnaires and consumer surveys, comprehensive Drug Facts label development and testing, as well as report writing including final study reports and briefing books for submission to FDA.
Janine also works in the areas of tobacco control and tobacco harm minimization, with a focus on research design and analysis and regulatory submissions. Given her extensive research and writing experience, she also writes scientific publications and has co-authored more than 30 published papers.
Janine joined PinneyAssociates in 1998. After receiving her doctorate in biobehavioral health from Penn State University in 1996, Janine completed a post-doctoral fellowship in human behavioral pharmacology at the University of Vermont in 1998. She has a broad research background in drug abuse, nicotine addiction and smoking cessation, the interaction of health and behavior, and health promotion and disease prevention.